AbbVie

Valuation Analysis

About the Company

AbbVie en bref

AbbVie (ABBV) is currently trading at 189,07 € with a market capitalization of 334,0 Md €. The trailing P/E ratio stands at 105.68x, with a forward P/E of 13.33x. The 52-week range spans from 158,59 € to 213,64 €; the current price is 11.5% below the yearly high. Year-over-year revenue growth stands at +12.4%. The net profit margin stands at 5.79%.

💰 Dividende

AbbVie pays an annual dividend of 6,04 € per share, representing a yield of 3.19%. The payout ratio stands at 325.98%. The elevated payout ratio reflects a mature dividend policy.

📊 Avis des analystes

29 analystes évaluent AbbVie (ABBV) au consensus : Acheter. L'objectif de cours moyen est de 221,27 €, soit un potentiel de +17.04% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 160,57 € à 286,24 €.

AbbVie : la thèse d'investissement en détail

AbbVie (ABBV) operates in the Healthcare — specifically Drug Manufacturers - General — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Revenue is growing at a healthy 12.4% pace year-over-year, suggesting the business model continues to find new customers and pricing power. With a gross margin near 72.03%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Wall Street consensus sits at Buy with an average price target implying roughly 17.04% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

A trailing P/E above 50 combined with revenue growth below 20% is a dangerous combination — the market is paying a steep growth multiple for what is, by the data, only moderately fast expansion. Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

Valorisation en contexte

With a PEG ratio of 0.61, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity.

À surveiller

• The forward P/E of 13.33x is meaningfully below the trailing 105.68x — analysts expect earnings to step up; the next earnings release is the test.

Thèse d'investissement : forces et faiblesses

Aperçu technique

The price is in a transition zone relative to the moving averages — no clear signal.

Profil de risque

The data points to relatively defensive market behavior.

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy AbbVie?

Compare top-rated brokers — low fees, trusted providers, fully regulated.